Dermatology Update 2016


Montréal, Le Centre Sheraton - NOVEMBER 3-6, 2016

Guiding the Clinician and Patient: Top 10 Things Both Should Know about IL-17 Inhibitors

Objectives and Description:

An improved understanding of the immune pathways involved in psoriasis has led to the development of new therapies that are targeted at more downstream mediators in the psoriatic cascade. New molecules that antagonize IL-17 have demonstrated an incremental benefit and allow physicians to help a greater proportion of patients achieve almost clear or clear skin.  With the recent approval of IL-17 inhibitors as a new class of biologic therapy the treatment paradigm is evolving for patients with moderate to severe psoriasis. Multiple factors enter into the equation when selecting a therapy for psoriasis, including disease severity, patient preference, efficacy, tolerability, relevant comorbidities and the evaluation of individual patient response. This session will focus on the top 10 things dermatologists say they want to know to be able to use anti IL-17’s in the clinical setting.

After attending this session, participants will be able to:

  1. Describe the role of interleukin (IL)-17 as a pivotal mediator of inflammation in psoriasis
  2. Assess key clinician and patient rated outcome data associated with novel anti IL-17 therapies
  3. Evaluate implications of the safety profile of IL-17 inhibitors for optimizing patient outcomes in psoriasis
  4. Confidently integrate anti IL-17s into clinical practice


11:00 – 11:05          Introduction

11:05 – 11:55          Top Ten Questions About IL-17s          Dr. Chih-ho Hong & Dr. Ron Vender

11:55 – 12:15          Q&A


Dr. Chih-Ho Hong

Dr. Chih-Ho Hong

Dermatologist, Surrey, British Columbia

Dr. Ron Vender

Dr. Ron Vender

Dermatologist, Hamilton, ON